Clorox raises FY25 adjusted EPS view to $6.65-$6.90 from $6.55-$6.80

FY25 consensus $6.65. The company continues to expect net sales to be flat to down 2%, consensus $6.99B. Organic sales are still expected to be up 3% to up 5%, excluding about 2 points of negative impact from the divestiture of the company’s business in Argentina and about 3 points of negative impact from the divestiture of the Better Health VMS business. Gross margin is now expected to be up about 100 to 150 basis points, primarily due to the benefits of holistic margin management efforts, partially offset by cost inflation and higher trade promotion spending. This compares to the previous expectation of about 100 basis points.